



## ISEV2025 ABSTRACT SUBMISSION GUIDELINES

### Introduction

The abstract submission guidelines for the ISEV2025 Congress are intended to provide clear instructions for submitting an abstract. You are kindly requested to carefully read the guidelines below before starting the submission process. ISEV and the ISEV2025 International Organizing Committee (IOC) maintain the right to reject any abstract that does not conform to these guidelines.

### Key dates:

<b>Abstract Launch</b>	Monday, September 2, 2024
<b>Abstract Close</b>	Sunday, November 03, 2024 at 11:59pm EST
<b>Author Notifications</b>	Monday, January 13, 2025
<b>Presenting Author of Abstracts Registration Deadline</b>	Monday, February 17, 2025
<b>Late Breaking Abstract Launch</b>	Monday, January 13, 2025
<b>Late Breaking Abstract Close</b>	Monday, February 03, 2025

### General abstract guidelines

1. Please consult the Minimal Information for Studies of EVs ([MISEV2023](#) – Linked Here) and ensure that your abstract is responsive to the guidelines, including on nomenclature, sample processing, separation, characterization, functional studies, and reporting.
2. The title of the abstract should not exceed 35 words, and the main body of the abstract should not exceed 350 words.
3. Separate the text by subheadings into Introduction, Methods, Results, Summary/Conclusions. Capitalize only the first letter of the first word of the title (unless for abbreviations or proper nouns) and do not end the title with a period (“.”). A correctly formatted example: “This abstract is about CD63-positive EVs”
4. The abstract must contain primary scientific or clinical data that have not been published elsewhere and have not been presented previously at an ISEV annual meeting.
5. The abstract submitter is responsible for ensuring that all authors have read the abstract and agreed to be co-authors. For submitters, the Name, Affiliation, City, Country, and contact information of each author is required. Clearly state the presenting author. Please collate this information prior to starting abstract submission.

6. Clearly indicate molecular findings with consensus names, not generic identifiers like “Protein X” and “miRNA Y”. Abstracts without these details may be rejected. Please note if a patent is pending and therefore limiting information disclosure.
7. Indicate if the research was performed or supported by a for-profit entity (e.g. industrial partner). Abstracts must contain scientific content. Out of fairness to ISEV sponsors, abstracts submitted by industry representatives may undergo additional review of the scientific content and may or may not be accepted. If you are an industry representative, kindly consider supporting ISEV as a meeting sponsor.
8. Submitted abstracts on human subjects must have ethical approval and state whether informed consent was obtained. Animal studies need to be approved by the relevant animal use committees.
9. If off-label/unlicensed use of drugs was involved in the study, please state this clearly. Indicate the funding agency of your work if applicable.
10. The abstract title and text may not contain trade names. ISEV reserves the right to replace trade names in accepted abstracts.
11. Do not partition results from the same study into multiple abstracts, and do not submit a copy or close copy of an abstract under more than one theme. ISEV reserves the right to reject abstracts when inappropriate partitioning of data is suspected.
12. Abstracts should be submitted in clear English. Authors are encouraged to have their abstract checked for grammar and spelling.
13. Choose the preferred presentation mode: oral or poster. Once accepted, all poster abstracts will be offered a poster presentation; however, only a limited number of oral-preference abstracts can be considered. The remainder will be offered poster presentations. If you are not comfortable with presenting and responding to questions in English, you are encouraged to present a poster.

## Abstract review, selection, and publication

An international panel of experts representing all subspecialties and geographical diversity will review all abstracts received. Each abstract will be reviewed by at least three reviewers, based on scientific novelty, completeness and including the MISEV2023 criteria where appropriate. The review will be “blinded”: that is, the reviewers will not have access to the names or institutions of the authors. The submitters and presenting authors will receive confirmation of acceptance for oral presentation, poster presentation, or a notice of rejection, by e-mail. No revisions can be made after the abstract deadline.

The highest ranked oral presentation preference abstracts will be selected for oral presentation. Authors of abstracts selected for oral presentation will be informed about the session and date of presentation, and presentation guidelines will be provided.

Poster presenters will be informed about the date of the poster session and will receive guidelines for preparation and presentation. High-quality abstracts accepted for poster presentation and submitted by junior investigators (<4 years after terminal degree) will also be considered for an oral “poster-pitch” to accompany poster presentation. All accepted abstracts will be published in The Journal of Extracellular Vesicles and will be made available on the congress website at the time of the meeting.

## Withdrawal policy

If authors wish to withdraw the abstracts from presentation or publication, they are requested to send an e-mail to ISEV (contact@isev.org) before 15 March 2025. All abstracts will be prepared for publication in The Journal of Extracellular Vesicles. Withdrawn abstracts cannot be presented or published.

## ISEV2025 Abstract Themes

To aid the review process, you will be requested to select from one of the following themes which best fits with the content of your abstract.

### **(1) EV sources and basic biology**

### **(2) Physiology and pathology**

### **(3) Disease and therapy**

### **(4) Technologies and methods**

#### (1) EV sources and basic biology

EV heterogeneity (including EV subtypes from diverse sources)

EV biogenesis (including cargo loading & release)

EV biochemical characteristics

EV biophysical and mesoscale characteristics

EV cell interaction

Fusion, uptake, transfer & bio-distribution of EV

EV-ECM interactions

EV Corona

Functional cell state-related EVs (including activated, dying, transformed, senescent, dividing & migrating)

Extracellular particles

EV signaling between organisms, species, and kingdoms

Microbes (including viruses, bacteria & fungi)

Parasite-derived EVs

Plants & algae EVs

EV mimetics and extruded EVs

Stem cell derived EVs (including MSC- and iPSC-derived EVs)

Alternative EV sources for therapy (including milk, immune cells, platelets & plants)

#### (2) Physiology and pathology

Cell reprogramming

Tissue remodeling

EVs in cell homeostasis

Immunology & immunity

Fertility & Reproduction

EVs in the gastrointestinal system (function and origin)

Heart & vascular

Kidney & urinary tract

Metabolism (including obesity, diabetes & liver diseases)

Musculoskeletal system & skin

Nervous system (central & periphery)

Pulmonary & lung

Host-pathogen interactions

Microbiome

Inter-organ communication (including tissue barriers)

Stress (including exercise and mental stress)

### (3) Disease and Therapy

EV biomarker development  
EV biomarker clinical translation (including regulatory & commercial aspects)  
EV biomarker technologies  
Cancer initiation & promotion  
Cancer progression & metastasis  
Metabolic diseases (incl. obesity, diabetes, liver)  
EV therapeutics development  
Biologic activity and therapeutic potency of EVs  
Disease/therapy relevant mechanism/s of action  
Pharmacokinetics and pharmacodynamics  
EV clinical trials (including pre-clinical studies)  
EVs in cancer immunotherapy  
EV Vaccines  
Regulatory compliance

### (4) Technologies and Methods

EV enrichment  
EV sizing and counting  
EV detection (including labelling & tracking)  
EV reporter systems  
EV reference materials  
Analysis of EV-cargo (including omics)  
Analysis of EV-biophysical properties  
Engineering and loading EVs  
Artificial EVs (including semi & fully synthetic)  
EV recognition (e.g. curvature sensing peptides)  
Assay development for EV biological function

## **Language setting of your keyboard**

The keyboard configuration of computers in some countries may cause problems with the printing of the abstracts when certain characters are used. To avoid these problems the language setting of your computer may need to be changed. To do this select "Start" then "Settings", then "Control Panel" and then choosing "Keyboard." Once in this menu, set the language of your computer to English (United States) or US (International). Next, open your word processing software and set the font type to Arial. In the preparation of your abstract, if you require certain special characters that are not available, (e.g. '±', '®', 'μ'), use the insert symbol feature (special characters). To do this, select Arial as the font, then select the required character, and copy and paste the symbol into the text of the abstract. If a special character is still not available, describe the character, e.g. 'alpha'.